ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2009
(Thomson Reuters ONE) - REGULATED INFORMATIONGHENT, Belgium, 10 November 2009 - Ablynx [Euronext Brussels: ABLX]today provides its non-audited business update in compliance with theEU transparency directive. This report summarises material events andAblynx's financial position for the third quarter of 2009. It hasbeen approved by the Board of Directors.Q3 2009 Highlights * Initiated an open-label, randomised Phase II study of its anti-thrombotic Nanobody®, ALX-0081, in patients undergoing percutaneous coronary intervention (PCI) * Announced positive results from its double-blind, randomised, placebo-controlled Phase I study with ALX-0681, a subcutaneous formulation of its novel anti-thrombotic Nanobody * Received a milestone payment of $4 million as Wyeth Pharmaceuticals initiated a Phase II multiple dose study of an anti-TNFa Nanobody in patients with rheumatoid arthritis * Increased revenues by 133% to ?21.9 million for the period January-September (2008: ?9.4 million) * ?93.7 million in cash at 30 September 2009Business UpdateRevenues increased over the first nine months by 133% to ?21.9million compared with the same period in 2008 (2008: ?9.4 million).Expenses increased by 46% to ?37.5 million (2008: ?25.6 million). Thenet loss for the first nine months of 2009 was ?13.5 million (2008:?12.1 million). The Company's total cash position(*) was ?93.7M million at 30 September 2009 (2008: ?119.8 million).(*) The Company's cash position is composed of cash, cash equivalentsand financial assets available-for-sale.Material events after 30 September 2009On 12 October, Ablynx reached a settlement with Domantis, part of theGlaxoSmithKline group of companies, concerning a dispute relating toa settlement agreement which Ablynx and Domantis entered into in2005. Under the terms of the agreement Ablynx received a license tothe European Winter II patent and will pay Domantis low single-digitroyalties on the first five Nanobody products which arecommercialised.For more information, please contact:College Hill Life Sciences - for UK/International media enquiries:Sue Charles, Justine Lamond, Dr John McIntyret: +44 (0)20 7866 7857f: +44 (0)20 7866 7900e: ablynx(at)collegehill.comAblynx:Dr Edwin MosesChairman and CEOt: +32 (0)9 262 00 07m: +44 (0)7771 954 193 / +32 (0)473 39 50 68e: edwin.moses(at)ablynx.comEva-Lotta AllanChief Business Officert: +32 (0)9 262 00 75m: +32 (0)475 78 36 21 / +44 (0)7990 570 900e: eva-lotta.allan(at)ablynx.comWim OttevaereChief Financial Officert: +32 (0)9 262 00 08e: wim.ottevaere(at)ablynx.comhttp://hugin.info/137912/R/1354059/328135.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 10.11.2009 - 18:14 Uhr
Sprache: Deutsch
News-ID 8183
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 242 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2009"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
